Hui Feng, MD, PhD will be a plenary session presenter at the International Zebrafish Genetics and Development Meeting being held at the University of Wisconsin-Madison in June. Dr. Feng will be speaking on Zebrafish Genetic Screens Identify DLST as a Potential Novel Therapeutic Target of Human Acute T-Lymphoblastic Leukemia/Lymphoma. She is the director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. This is the tenth year of the meeting, which focuses on using zebrafish as a genetic model system to understand development and disease.
Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia. Her research strategy is to combine the analysis of human cancer genomic databases with the genetic and imaging capacities of the zebrafish system. Her long-term goal is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.
Dr. Feng is assistant professor of Pharmacology and Medicine, Division of Hematology and Medical Oncology at Boston University School of Medicine.